The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) is an organization composed of neuro-ophthalmologists and other doctors, structured to perform prospective clinical research. Neuro-Ophthalmology is a subspecialty of Neurology and Ophthalmology that addresses scientific and medical aspects that bridge both specialties. There is a broad spectrum of Neuro-ophthalmologic disorders that collectively affect millions of people. Many of these are visual disorders associated with other systemic or neurological conditions and many fit the US Government definition as """"""""rare"""""""" diseases and have not been adequately investigated. The Network is prepared to conduct studies on two of these disorders: idiopathic intracranial hypertension and thyroid eye disease. There is little consensus among practitioners on the diagnostic evaluation or therapy for many neuro-ophthalmological disorders. NORDIC will provide the organization and operational capability to perform multi-site observational and treatment trials, involving nearly 200 community and academic practitioners, in order to address the many crucial yet unanswered questions about risks, diagnosis, treatment and other management-aspects of these diseases that could not be studied without a clinical research organization. The NORDIC strategy is to provide a strong Central Coordination, to an open network of investigators at sites, in order to conduct multiple trials in parallel, employing protocols that can be incorporated into standard clinical practice. The strong central coordination is provided by: the NORDIC Chair and Executive Committee who are recognized leaders in neuroophthalmic and clinical research;the use of steering committees for each study;a Data Coordination and Biostatistics Center that is expert at national, multi-site studies;and reading centers appropriate for neuroophthalmic assessments. The open network and structure will allow practitioners to develop new studies, become certified and participate in specific studies and protocols, as appropriate to their expertise and interests. This approach will allow the recruitment and study of powerful numbers of otherwise-hard-to-find study patients, with a high degree of control over the scientific quality of the research projects. The products of the NORDIC strategy will be evidence-based diagnostic and treatment solutions that can be applied to enhance the visual health of a significant portion of the population.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10EY017281-04
Application #
8238355
Study Section
Special Emphasis Panel (ZEY1-VSN (05))
Program Officer
Schron, Eleanor
Project Start
2009-02-06
Project End
2014-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
4
Fiscal Year
2012
Total Cost
$1,716,841
Indirect Cost
$476,173
Name
St. Luke's-Roosevelt Institute for Health Sciences
Department
Type
DUNS #
623216371
City
New York
State
NY
Country
United States
Zip Code
10019
Sibony, Patrick A; Kupersmith, Mark J; OCT Substudy Group of the NORDIC Idiopathic Intracranial Hypertension Treatment Trial (2016) ""Paton's Folds"" Revisited: Peripapillary Wrinkles, Folds, and Creases in Papilledema. Ophthalmology 123:1397-9
Peragallo, Jason H; Bitrian, Elena; Kupersmith, Mark J et al. (2016) Relationship Between Age, Gender, and Race in Patients Presenting With Myasthenia Gravis With Only Ocular Manifestations. J Neuroophthalmol 36:29-32
Cello, Kimberly E; Keltner, John L; Johnson, Chris A et al. (2016) Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial. J Neuroophthalmol 36:6-12
ten Hove, Martin W; Friedman, Deborah I; Patel, Anil D et al. (2016) Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial. J Neuroophthalmol 36:13-9
Kupersmith, Mark J; Garvin, Mona K; Wang, Jui-Kai et al. (2016) Retinal ganglion cell layer thinning within one month of presentation for optic neuritis. Mult Scler 22:641-8
Wall, Michael; Johnson, Chris A; Cello, Kimberly E et al. (2016) Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci 57:805-12
Kattah, Jorge C; Pula, John H; Mejico, Luis J et al. (2015) CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial. J Neurol 262:2271-4
Kupersmith, Mark J (2015) Optical imaging of the optic nerve: beyond demonstration of retinal nerve fiber layer loss. J Neuroophthalmol 35:210-9
Optical Coherence Tomography Substudy Committee; NORDIC Idiopathic Intracranial Hypertension Study Group (2015) Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial. Ophthalmology 122:1939-45.e2
Chen, John J; Thurtell, Matthew J; Longmuir, Reid A et al. (2015) Causes and Prognosis of Visual Acuity Loss at the Time of Initial Presentation in Idiopathic Intracranial Hypertension. Invest Ophthalmol Vis Sci 56:3850-9

Showing the most recent 10 out of 29 publications